Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia

International Journal of Neuropsychopharmacology

Volumn 18, Issue 6, 2015, Pages 1-6

  Fedorenko, Olga Yu ^a,b   Loonen, Anton J M ^c,d   Lang, Florian ^e   Toshchakova, Valentina A ^a   Boyarko, Evgenia G ^a   Semke, Arkadiy V ^a   Bokhan, Nikolay A ^a,g   Govorin, Nikolay V ^f   Aftanas, Lyubomir I ^h   Ivanova, Svetlana A ^a,b  

^a MENTAL HEALTH RESEARCH INSTITUTE   (Russian Federation)

^b NATIONAL RESEARCH TOMSK POLYTECHNIC UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Department of Severe Mental Illness   (Netherlands)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f CHITA STATE MEDICAL ACADEMY   (Russian Federation)

^g TOMSK STATE UNIVERSITY   (Russian Federation)

^h SCIENTIFIC RESEARCH INSTITUTE OF PHYSIOLOGY AND BASIC MEDICINE   (Russian Federation)

Author keywords

gene polymorphism; medium spiny neurons; neurotoxicity; PIP5K2A; schizophrenia; tardive dyskinesia

Indexed keywords

1 PHOSPHATIDYLINOSITOL 4 PHOSPHATE 5 KINASE TYPE IIA; PHOSPHATIDYLINOSITOL 4 PHOSPHATE KINASE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT; PHOSPHOTRANSFERASE; PIP4K2A PROTEIN, HUMAN;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; CLINICAL TRIAL; DYSKINESIA, DRUG-INDUCED; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MOVEMENT DISORDERS; MULTICENTER STUDY; PHENOTYPE; PROTECTION; RISK ASSESSMENT; RISK FACTOR; RUSSIAN FEDERATION; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SIBERIA; YOUNG ADULT;

EID: 84939192245     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu098     Document Type: Article

References (30)

1. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JR, Wilffert B, Brugge-man R, Loonen AJ (2009) Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpa-tients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 33:475-481.
2. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Wilffert B, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JR, Loonen AJ (2010) Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychophar-macol 25:84-91.
3. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67:255-262.
4. Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, Selten JP, Pearson PL, Kahn RS, Sinke RJ (2007) The PIP5K2A and RGS4 genes are differentially associated with defcit and non-defcit schizophrenia. Genes Brain Behav 6:113-119.
5. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
6. Estrada Sanchez AM, Mejia Toiber J, Massieu L (2007) Excitotoxic neuronal death and the pathogenesis of huntington's disease. Arch Med Res 39:265-276.
7. Fan MM, Raymond LA (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in huntington's disease. Prog Neurobiol 81:272-293.
8. Fedorenko O, Strutz-Seebohm N, Henrion U, Ureche ON, Lang F, Seebohm G, Lang UE (2008) A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels. Psychop-harmacology (Berl) 199:47-54.
9. Fedorenko O, Tang C, Sopjani M, Föller M, Gehring EM, Strutz-Seebohm N, Ureche ON, Ivanova S, Semke A, Lang F, Seebohm G, Lang UE (2009) PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. Psychopharmacology (Berl) 206:429-435.
10. Fedorenko O, Rudikov EV, Gavrilova VA, Boiarko EG, Semke AV, Ivanova SA (2013) Association of (N251S)-PIP5K2A with schizophrenic disorders: a study of the Russian population of Siberia. Zh Nevrol Psikhiatr Im S S Korsakova 113:58-61.
11. Glazer WM (2000) Review of incidence studies of tardive dyski-nesia associated with typical antipsychotics. J Clin Psychiatry 61 (Suppl 4):15-20.
12. He Z, Li Z, Shi Y, Tang W, Huang K, Ma G, Zhou J, Meng J, Li H, Feng G, He L (2007) The PIP5K2A gene and schizophrenia in the Chinese population; a case-control study. Schizophr Res 94:359-365.
13. Ivanova SA, Loonen AJ, Pechlivanoglou P, Freidin MB, Al Hadithy AF, Rudikov EV, Zhukova IA, Govorin NV, Sorokina VA, Fedorenko OY, Alifrova VM, Semke AV, Brouwers JR, Wilffert B (2012) NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry 2:e67.
14. Kane JM (2006) Tardive dyskinesia circa 2006. Am J Psychiatry 163:1316-1318.
15. Kane JM, Woerner M, Lieberman J (1988) Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharma-col 8:52S-56S.
16. Koning JP, Kahn RS, Tenback DE, van Schelven LJ, van Harten PN (2011a) Movement disorders in nonpsychotic siblings of patients with nonaffective psychosis. Psychiatry Res 188:133-137.
17. Koning JP, Tenback DE, Kahn RS, Vollema MG, Cahn W, van Harten PN (2011b) Movement disorders are associated with schizotypy in unaffected siblings of patients with non-affective psychosis. Psychol Med 41:2141-2147.
18. Kumar P, Kalonia H. Kumar A (2010) Huntington's disease: patho-genesis to animal models. Pharmacol Rep 62:1-14.
19. Lohr JB, Kuczenski R, Niculescu AB (2003) Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17:47-62.
20. Loonen AJ, Ivanova SA (2013) New insights into the mechanism of drug-induced dyskinesia. CNS Spectr 18:15-20.
21. Loonen AJ, Van Praag HM (2007) Measuring movement disorders in antipsychotic drug trials: the need to defne a new standard. J Clin Psychopharmacol 27:423-430.
22. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 50:541-547.
23. Paoletti P, Neyton J (2007) NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7:39-47.
24. Saggers-Gray L, Heriani H, Handoko HY, Irmansyah I, Kusuma-wardhani AA, Widyawati I, Amir N, Nasrun MW, Schwab SG, Wildenauer DB (2008) Association of PIP5K2A with schizophrenia: a study in an Indonesian family sample. Am J Med Genet B Neuropsychiatr Genet 147B:1310-1313.
25. Schooler NR, Kane JM (1982) Research diagnoses for tardive dys-kinesia. Arch Gen Psychiatry 39:486-487.
26. Schwab SG, Knapp M, Sklar P, Eckstein GN, Sewekow C, Borrmann-Hassenbach M, Albus M, Becker T, Hallmayer JF, Lerer B, Maier W, Wildenauer DB (2006) Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIalpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 11:837-846.
27. Seebohm G, Wrobel E, Pusch M, Dicks M, Terhag J, Matschke V, Rothenberg I, Ursu ON, Hertel F, Pott L, Lang F, Schulze-Bahr E, Hollmann M, Stoll R, Strutz-Seebohm N (2014) Structural basis of PI(4, 5)P2-dependent regulation of GluA1 by phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (PIP5K2A). Pfugers Arch 466:1885-1897.
28. Tenback DE, van Harten PN (2011) Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol 98:211-230.
29. Unoki T, Matsuda S, Kakegawa W, Van NT, Kohda K, Suzuki A, Funa-koshi Y, Hasegawa H, Yuzaki M, Kanaho Y (2012) NMDA receptor-mediated PIP5K activation to produce PI(4, 5)P2 is essential for AMPA receptor endocytosis during LTD. Neuron 73:135-148.
30. Van den Bout I, Divecha N (2009) PIP5K-driven PtdIns(4, 5)P2 synthesis: regulation and cellular functions. J Cell Sci 122:3837-3850.